Alnylam Pharmaceuticals (United States)
In research, Alnylam Pharmaceuticals (United States) stands highest in Life Sciences (#3,644 of 14,347 worldwide), Molecular Biology (#1,420 of 4,961 worldwide) and Biochemistry, Genetics and Molecular Biology (#2,412 of 7,814 worldwide), over all time. Relative to its size it is most specialised in Molecular Biology and Biochemistry, Genetics and Molecular Biology — Molecular Biology is 12.6× its share of world research.
- World rank, 2022–2025
- #13,768 of 28,054 · #9,405 all time
- Rank in United States
- #1,920 of 4,192
- Research works
- 344 ▲ 134% vs 2013–17
- Citations
- 25k 73.5 per fractional work
- Top-10% rate
- 18.5% record average 16.5%
- Open access
- 50% world 28%
What is Alnylam Pharmaceuticals (United States) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Life SciencesDomain | #3,644 of 14,347 | 34.9% | 210 | |
| Molecular BiologySubfield | #1,420 of 4,961 | 34.9% | 152 | |
| Biochemistry, Genetics and Molecular BiologyField | #2,412 of 7,814 | 35.5% | 190 |
Each strip is that field’s whole ranked pool, with the notch where Alnylam Pharmaceuticals (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Alnylam Pharmaceuticals (United States) specialise in?
Where its research is concentrated relative to its size: Molecular Biology takes 12.6× the share of its output that it takes of world research.
- Molecular BiologySubfield · 36.0 works13×
- Biochemistry, Genetics and Molecular BiologyField · 45.8 works9.1×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 9.1×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 9.1×
- Immunology and Microbiology 2.6×
- Pharmacology, Toxicology and Pharmaceutics 2.1×
- Medicine 1.9×
- Nursing 1.4×
- Veterinary 1.4×
- Neuroscience 0.9×
- Decision Sciences 0.9×
- Chemistry 0.7×
- Mathematics 0.3×
- Economics, Econometrics and Finance 0.3×
- Agricultural and Biological Sciences 0.2×
- Psychology 0.2×
- Physics and Astronomy 0.2×
- Engineering 0.1×
- Earth and Planetary Sciences 0.1×
- Arts and Humanities 0.1×
- Computer Science 0.1×
- Materials Science 0.1×
- Environmental Science 0.0×
- Social Sciences 0.0×
- Health Professions 0.0×
Who are the top researchers at Alnylam Pharmaceuticals (United States)?
Ranked on the composite score, Jared Gollob, Akshay Vaishnaw and Marianne T. Sweetser lead among researchers whose main affiliation is Alnylam Pharmaceuticals (United States).
- 1 Jared Gollob United States · #53,636 worldwide 481 citations · 39 works
- 2 Akshay Vaishnaw United States · #130,542 worldwide 459 citations · 21 works
- 3 Marianne T. Sweetser United States · #172,795 worldwide 446 citations · 18 works
- 4 Brian R. Bettencourt United States · #885,797 worldwide 84 citations · 16 works
- 5 Joo‐Hwan Kim United States · #1,244,244 worldwide 58 citations · 25 works
Which keywords describe research at Alnylam Pharmaceuticals (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Treatment, Diagnosis, Gene Therapy, Prognosis, Cardiovascular Magnetic Resonance, RNA Interference, siRNA Delivery and Cardiac Amyloidosis.
- phosphate
- Parathyroid Hormone
- Neuroprotection
- DNA Structure
- Antisense Oligonucleotides
- Therapeutic Targets
- Chronic Kidney Disease
- Risk Factors
- Heme Biosynthesis
- Genomic Analysis
- Hypertension
- Self-Assembly
- Biosensors
- Nanoparticles
- Genetic Mutations
- Oxidative Stress
- Cardiac Amyloidosis
- RNA Interference
- Prognosis
- Diagnosis
- Treatment
- Gene Therapy
- Cardiovascular Magnetic Resonance
- siRNA Delivery
- Transthyretin
- Inflammation
- Vitamin B12
- Metabolic Syndrome
- DNA nanotechnology
- Liver Transplantation
- Cardiovascular Disease
- Cancer
- Porphyrias
- Management
- Apoptosis
- Nucleic Acids
- Cardiovascular Events
- G-Quadruplexes
- Mitochondrial Dysfunction
- FGF23
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Treatment11▲ 9.5×12 topics
- Diagnosis9▲ 10×9 topics
- Gene Therapy8▲ 46×3 topics
- Prognosis8▲ 26×5 topics
- Cardiovascular Magnetic Resonance8▲ 153×2 topics
- RNA Interference8▲ 94×1 topic
- siRNA Delivery8▲ 135×1 topic
- Cardiac Amyloidosis7▲ 372×1 topic
- Transthyretin7▲ 372×1 topic
- Oxidative Stress7▲ 4.6×17 topics
- Inflammation6▲ 3.3×27 topics
- Genetic Mutations5▲ 13×8 topics
- Vitamin B125▲ 162×2 topics
- Nanoparticles5▲ 4.3×6 topics
- Metabolic Syndrome5▲ 6.4×10 topics
- Biosensors5▲ 9.9×2 topics
- DNA nanotechnology5▲ 41×1 topic
- Self-Assembly5▲ 16×1 topic
- Liver Transplantation5▲ 41×4 topics
- Hypertension4▲ 16×9 topics
- Cardiovascular Disease4▲ 4.0×13 topics
- Genomic Analysis4▲ 18×3 topics
- Cancer4▲ 3.1×18 topics
- Heme Biosynthesis4▲ 628×1 topic
- Porphyrias4▲ 628×1 topic
- Risk Factors4▲ 3.5×8 topics
- Management3▲ 4.2×4 topics
- Chronic Kidney Disease3▲ 14×6 topics
- Apoptosis3▲ 9.6×6 topics
- Therapeutic Targets3▲ 19×3 topics
- Nucleic Acids3▲ 100×2 topics
- Antisense Oligonucleotides2▲ 63×2 topics
- Cardiovascular Events2▲ 22×2 topics
- DNA Structure2▲ 130×1 topic
- G-Quadruplexes2▲ 130×1 topic
- Neuroprotection2▲ 7.2×4 topics
- Mitochondrial Dysfunction2▲ 8.4×7 topics
- Parathyroid Hormone2▲ 27×3 topics
- FGF232▲ 68×1 topic
- phosphate2▲ 68×1 topic
Which research topics does Alnylam Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: RNA Interference and Gene Delivery, Amyloidosis: Diagnosis, Treatment, Outcomes, Advanced biosensing and bioanalysis techniques and Porphyrin Metabolism and Disorders.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 RNA Interference and Gene Delivery Molecular Biology 8 works
- 2 Amyloidosis: Diagnosis, Treatment, Outcomes Molecular Biology 7 works
- 3 Advanced biosensing and bioanalysis techniques Molecular Biology 5 works
- 4 Porphyrin Metabolism and Disorders Molecular Biology 4 works
- 5 DNA and Nucleic Acid Chemistry Molecular Biology 2 works
- 6 Parathyroid Disorders and Treatments Nephrology 2 works
- 7 Kidney Stones and Urolithiasis Treatments Pulmonary and Respiratory Medicine 2 works
- 8 Heme Oxygenase-1 and Carbon Monoxide Molecular Biology 2 works
- 9 MicroRNA in disease regulation Cancer Research 2 works
- 10 Alzheimer's disease research and treatments Physiology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Alnylam Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 134% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- Harvard University
- Massachusetts Institute of Technology
- Center for Astrophysics Harvard & Smithsonian
- National Bureau of Economic Research
- IIT@MIT
- World Wide Web Consortium
- Broad Institute
- Smithsonian Astrophysical Observatory
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.